review Archives - Page 3 of 3

The clinical insights gained from T-cell receptor sequencing in revealing the immune characteristics of liver cancer staging

By Mourabit Halima 2024.01.08

T lymphocytes play a crucial role in human adaptive immunity by recognizing antigens major histocompatibility complex (MHC) molecules through specific T-cell receptors (TCRs) on their surface. 95% of T cells have TCRs composed of α and β peptide chains connected by disulfide bonds, forming an α/β heterodimer. Each chain consists of constant and variable domains. TCR diversity arises from the rearrangement of the variable (V), diversity (D), and joining (J) gene segments of the peptide chains, along with random nucleotide additions or deletions.

APASL 2023 | Prof. Rao Huiying: Eliminating HCV, Key Issues That Still Need Attention

By Lisa Cui 2024.01.07

Chronic HCV infection is a global public health issue. With the widespread use of direct-acting antiviral agents (DAAs), chronic hepatitis C (CHC) has become a curable disease. However, after successful HCV clearance and achieving sustained virological response (SVR), do CHC patients still face risks of liver-related events? Currently, there is a significant gap in reaching the World Health Organization's goal of eliminating viral hepatitis as a major public health threat by 2030. How can we achieve near-elimination of HCV? At the 32nd annual meeting of the Asia-Pacific Association for the Study of the Liver (APASL), Professor Rao Huiying from Peking University People's Hospital, China, was invited as our special correspondent to bring four significant research findings in this field to our readers, providing insightful interpretations and summaries.

Dr. Ming Zhao: Key Clinical Research in Hepatocellular Carcinoma｜Highlights from APPLE 2023

By Lynn 2023.10.23

From July 6th to 8th, 2023, the 13th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2023) was held in Seoul, South Korea. Hepatocellular carcinoma (HCC) experts from around the world gathered to rekindle academic discussions on HCC's basics, clinical aspects, research, and technology offline. The conference featured the latest research results from over a thousand scholars representing more than 50 countries. In this publication, Dr. Ming Zhao from Sun Yat-sen University Cancer Center, China, offers insightful interpretations of the significant clinical research emerging from APPLE 2023 for the benefit of our readers.

Dr. Lang Bai: The Impact and Mechanism of TmPV1 Fungivirus on Talaromyces Marneffei Virulence

By Peter W. PENG 2023.10.22

Editor's Note: Over the years, significant progress has been made in the prevention and treatment of HIV/AIDS and co-infections. Society has provided the best medications and professional knowledge to combat HIV infections, making substantial contributions to those affected. From June 8th to 10th, 2023, the Asia-Pacific AIDS and Co-Infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to invite Dr. Lang Bai, Deputy Director of the Infectious Diseases Center, West China Hospital, Sichuan University, China, to share with us the latest research on Talaromyces marneffei infection, a common fungal disease among AIDS patients and other immunocompromised individuals in Southeast Asia.

Dr. Hongzhou Lu: Focus on the Aging of HIV/AIDS Patients, Intrinsic Capacity Assessment is Imperative!

By Peter W. PENG 2023.10.22

Editor's Note: In recent years, with the effectiveness of antiretroviral therapy (ART) in suppressing HIV replication, the life expectancy of HIV-infected individuals has significantly increased. At the same time, the trend of aging among HIV/AIDS patients has gradually become a research hotspot in the field. From June 8th to 10th, 2023, the Asia Pacific AIDS and Co-infections Conference (APACC 2023) was held in Singapore. In this issue, we are honored to have Dr. Hongzhou Lu from Shenzhen Third People's Hospital share with us the latest research on the aging of HIV/AIDS patients.

Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

By Peter W. PENG 2023.10.12

Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference ( IAS 2023), Dr. A. Cozzi-Lepri of University College London reported a study (Abstract number: EPB0169) that analyzed and evaluated the risk of ART switches in the context of common comorbidities combined with HIV and suppressed HIV RNA. This journal specially invited Dr. Biao Zhu from the First Affiliated Hospital of Zhejiang University School of Medicine, China, to provide a brilliant review of this research.

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

By Peter W. PENG 2023.10.12

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.

Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

By Peter W. PENG 2023.10.12

The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the health outcomes of People Living with HIV (PLWH). Dr.Yun He from the Third People's Hospital of Shenzhen, China, was specially invited to comment on the study as follows.

Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care

By Peter W. PENG 2023.10.12

AIDS remains one of the most significant public health issues worldwide, with around 38 million people living with HIV (PLWH). In recent years, with the continuous advancement of antiretroviral therapy (ART), AIDS has gradually transformed into a manageable chronic disease. However, PLWH still face challenges like poor drug adherence and increased risk of resistance.